

# **Vulvar Cancer Market – Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028**

## **Segmented By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy), By End-User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region, Competition**

<https://marketpublishers.com/r/VE35DA8A7548EN.html>

Date: November 2023

Pages: 178

Price: US\$ 4,500.00 (Single User License)

ID: VE35DA8A7548EN

### **Abstracts**

Global Vulvar Cancer Market is anticipated to project impressive growth in the forecast period. The Global Vulvar Cancer Market is a dynamic segment within the broader landscape of cancer care and treatment. Understanding its market overview is essential for comprehending the trends, challenges, and opportunities that shape this sector. In this article, we provide an in-depth analysis of the Global Vulvar Cancer Market, covering its current state, key players, growth drivers, challenges, and future prospects.

Vulvar cancer is a relatively rare form of cancer, accounting for approximately 4% of all gynecological cancers. The incidence rates vary by region, with higher rates in developed countries, particularly North America and Europe. The incidence is most common in older women, typically over the age of 65, but it can affect women of all ages.

### **Key Market Drivers**

## Rising Incidence Rates

One of the foremost drivers of the Global Vulvar Cancer Market is the alarming increase in incidence rates. This form of cancer primarily affects women and is characterized by the development of malignant cells in the vulva.

Lifestyle choices play a pivotal role in the increasing incidence of vulvar cancer. The adoption of unhealthy lifestyles, including smoking and poor dietary habits, has contributed significantly to the surge in vulvar cancer cases. These choices can lead to obesity, which is a well-established risk factor for vulvar cancer. Moreover, the prevalence of sexually transmitted infections (STIs) among individuals engaging in risky sexual behaviors has also played a role in driving up incidence rates. As the global population continues to age, the risk of developing vulvar cancer increases. This is primarily because vulvar cancer is more commonly diagnosed in older women. The demographic shift towards an older population contributes to the higher incidence rates observed in recent years. The aging population also means a larger pool of individuals at risk.

Understanding the various risk factors associated with vulvar cancer is essential. Apart from lifestyle choices and age, several factors can increase the susceptibility to this disease. Chronic inflammatory skin conditions, such as lichen sclerosus, can predispose individuals to vulvar cancer. Additionally, infection with certain strains of human papillomavirus (HPV) has been linked to an elevated risk of developing vulvar cancer. A lack of awareness and limited access to healthcare services can contribute to delayed diagnosis and treatment. Many women are unaware of the symptoms of vulvar cancer, leading to delayed reporting and diagnosis. This lack of awareness can result in more advanced stages of cancer at the time of diagnosis, making treatment more challenging.

## Advances in Medical Technology

The major driver of the Global Vulvar Cancer Market is the continuous advancement in medical technology. These innovations have revolutionized the diagnosis and treatment of vulvar cancer. One of the most significant contributions of medical technology is the development of more accurate and less invasive diagnostic methods. Advanced imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, enable early detection of vulvar cancer. This early detection can lead to more effective treatment and improved outcomes for patients. Also, the field

of surgery has seen remarkable progress with the introduction of minimally invasive techniques. Laparoscopic and robotic-assisted surgeries have reduced the trauma associated with traditional open surgeries, leading to shorter hospital stays and faster recoveries for patients.

Medical technology has also paved the way for targeted therapies in the treatment of vulvar cancer. These therapies are designed to specifically target cancer cells while sparing healthy tissue, reducing the side effects associated with traditional chemotherapy.

### Pharmaceutical Research and Development

Pharmaceutical research and development represent the major driver of the Global Vulvar Cancer Market. The continuous quest for more effective treatments and therapies has led to significant advancements in cancer care.

Researchers are constantly exploring new drug compounds and treatment regimens for vulvar cancer. Clinical trials are instrumental in evaluating the efficacy and safety of these new treatments. Recent discoveries have included immunotherapy options and targeted therapies tailored to specific genetic mutations found in vulvar cancer. The era of personalized medicine has arrived, and this extends to vulvar cancer treatment. Genetic profiling of tumors allows oncologists to tailor treatment plans to the individual patient, increasing the likelihood of success while minimizing side effects.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers has accelerated the development and availability of novel treatments for vulvar cancer. This synergy has expanded treatment options and improved patient outcomes.

### Government Initiatives and Healthcare Policies

This is shaping the Global Vulvar Cancer Market is government initiatives and healthcare policies. Governments and healthcare authorities worldwide have recognized the need to address the challenges posed by vulvar cancer.

Many countries have implemented screening programs aimed at early detection of vulvar cancer. These programs often target high-risk populations, offering regular screenings and educational campaigns to raise awareness. Governments have also worked to ensure that individuals diagnosed with vulvar cancer have access to

appropriate treatment options. This includes subsidizing the cost of therapies, reducing financial barriers, and improving the overall quality of care.

Government funding for vulvar cancer research has increased, supporting innovative studies and clinical trials. This financial support is instrumental in driving progress in understanding the disease and developing new treatment modalities.

The Global Vulvar Cancer Market is influenced by four major drivers: rising incidence rates, advances in medical technology, pharmaceutical research and development, and government initiatives and healthcare policies. These drivers work in tandem to shape the landscape of vulvar cancer care, impacting everything from diagnosis to treatment and long-term outcomes. As we continue to navigate this complex field, staying informed about these drivers is essential for healthcare professionals, policymakers, and patients alike.

## Key Market Challenges

### Limited Awareness and Early Detection

One of the primary challenges confronting the Global Vulvar Cancer Market is the limited awareness of this specific form of cancer among the general public. Unlike more prevalent cancers, such as breast or lung cancer, vulvar cancer often remains in the shadows. This lack of awareness results in delayed diagnosis, as symptoms are not recognized promptly. Many women may ignore warning signs or attribute them to less serious conditions, causing a delay in seeking medical attention.

Sociocultural taboos and stigmas surrounding reproductive and genital health can exacerbate the problem. Open discussions about vulvar cancer symptoms and prevention are often discouraged or considered taboo in many societies. This silence further contributes to the lack of awareness and inhibits early detection efforts. Early detection of vulvar cancer is crucial for successful treatment and improved outcomes. Delayed diagnosis can lead to more advanced stages of the disease, necessitating more aggressive and costly treatments. Addressing the challenge of limited awareness and early detection requires educational campaigns, public health initiatives, and healthcare providers actively promoting regular check-ups and screening for at-risk populations.

### Limited Access to Specialized Care

Access to specialized care for vulvar cancer is not uniform across regions and countries. In some areas, especially in rural or underserved communities, access to healthcare facilities with expertise in vulvar cancer diagnosis and treatment is limited. Patients in such regions may face longer wait times for diagnosis and treatment, which can adversely affect their prognosis.

The cost of vulvar cancer treatment, including surgery, radiation therapy, and targeted therapies, can be substantial. In many healthcare systems, these costs may not be fully covered by insurance, leaving patients with significant financial burdens. This financial strain can lead to delayed or inadequate treatment, impacting patient outcomes. The availability of advanced healthcare infrastructure, including state-of-the-art diagnostic tools and experienced medical professionals, also plays a role. Regions with underdeveloped healthcare infrastructure may struggle to provide timely and effective care for vulvar cancer patients.

### Research Funding and Innovation

While progress has been made in the treatment of vulvar cancer, it remains a relatively rare disease compared to more common cancers. Consequently, research funding dedicated to vulvar cancer may be limited in comparison. This lack of investment can hinder the development of new treatment modalities and therapies, potentially restricting the options available to patients.

Vulvar cancer is a complex disease with various subtypes and genetic mutations that can impact treatment responses. Research efforts to unravel the intricacies of the disease and identify targeted therapies are ongoing but face challenges due to limited resources. Encouraging patient participation in clinical trials is essential for advancing vulvar cancer treatment. However, recruitment for these trials can be challenging due to the rarity of the disease and the stringent eligibility criteria. This can slow down the pace of clinical research and delay the introduction of innovative treatments.

### Key Market Trends

#### Advances in Targeted Therapies and Immunotherapy

One of the most prominent trends in the Global Vulvar Cancer Market is the rapid advancement of targeted therapies and immunotherapy. Traditional cancer treatments, such as chemotherapy and radiation therapy, can be associated with significant side effects due to their nonspecific nature. However, the development of targeted therapies

has ushered in a new era of precision medicine. These therapies are designed to specifically target the molecular abnormalities present in vulvar cancer cells while sparing healthy tissues. This approach not only enhances treatment efficacy but also minimizes adverse effects.

Immunotherapy, a groundbreaking approach that harnesses the body's immune system to fight cancer, has gained considerable traction in recent years. It has shown promise in treating various cancer types, including vulvar cancer. Immunotherapeutic agents, such as immune checkpoint inhibitors, have demonstrated encouraging results in clinical trials. They work by blocking the mechanisms that tumors use to evade the immune system, allowing the body to mount a more robust anti-cancer response. These advancements enable oncologists to tailor treatment plans to each patient's unique genetic profile and the specific characteristics of their vulvar cancer. This personalized approach holds great potential for improving patient outcomes and minimizing treatment-related toxicity.

### Increasing Emphasis on Early Detection and Screening Programs

Early detection remains a cornerstone of effective vulvar cancer management. Recognizing the importance of early diagnosis, healthcare systems and organizations are placing a greater emphasis on screening programs for at-risk populations. These programs aim to detect vulvar cancer at its earliest, most treatable stage.

Risk-based screening approaches are gaining traction, focusing on high-risk groups such as women with a history of chronic vulvar skin conditions or human papillomavirus (HPV) infection. Regular gynecological check-ups and vulvar examinations are promoted to detect any abnormalities promptly. Technological advancements, including advanced imaging techniques and minimally invasive biopsy procedures, have improved the accuracy and accessibility of vulvar cancer screening. Magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and colposcopy play pivotal roles in early detection.

### Increasing Prevalence of High-Risk Factors

The demographic landscape is undergoing significant changes, with an aging population contributing to the increased prevalence of vulvar cancer. Vulvar cancer is most commonly diagnosed in older women, and as life expectancy continues to rise worldwide, the number of cases is expected to increase.



The global obesity epidemic is another significant trend driving the incidence of vulvar cancer. Obesity is a well-established risk factor for this type of cancer. As unhealthy lifestyles and poor dietary habits persist, the prevalence of obesity grows, further fueling vulvar cancer cases. Human papillomavirus (HPV) infection is a known risk factor for vulvar cancer. The prevalence of high-risk HPV strains, particularly HPV-16 and HPV-18, has led to an increase in HPV-related vulvar cancer cases. Efforts to expand HPV vaccination coverage aim to reduce this risk.

## Segmental Insights

### Cancer Type Insights

Based on the category of Cancer Type, the Vulvar Squamous Cell Carcinoma (VSCC) segment emerged as the dominant player in the global market for Vulvar Cancer in 2022. Vulvar Squamous Cell Carcinoma is the most common type of vulvar cancer, representing approximately 90% of all cases. Its high incidence rates contribute significantly to its dominance within the Global Vulvar Cancer Market. This prevalence can be attributed to various risk factors, including age, HPV infection, smoking, and chronic vulvar skin conditions.

Efforts to detect vulvar cancer at an early, treatable stage have largely focused on Vulvar Squamous Cell Carcinoma due to its frequency. Routine gynecological examinations and screening programs often prioritize the detection of squamous cell carcinomas. Early diagnosis can lead to less invasive treatment options and better prognoses, making VSCC a central concern for healthcare professionals. The dominance of Vulvar Squamous Cell Carcinoma has also been influenced by the significant progress made in its treatment. Researchers have developed targeted therapies and immunotherapies specifically tailored to combat squamous cell carcinomas. These innovative treatments have improved the outlook for VSCC patients, further cementing its position within the market.

VSCC's prominence within the Global Vulvar Cancer Market has been bolstered by public awareness campaigns and education efforts. The recognition of the importance of early detection and risk reduction strategies has contributed to more women seeking medical attention and understanding the associated symptoms. Due to its prevalence and clinical significance, Vulvar Squamous Cell Carcinoma has been the subject of extensive research. Clinical trials, molecular studies, and genetic profiling efforts have all been directed toward gaining a deeper understanding of VSCC. This research has led to the development of targeted therapies and personalized treatment plans. These

factors are expected to drive the growth of this segment.

### Treatment Insight

Based on the category of Treatment, the Surgery segment emerged as the dominant player in the global market for Vulvar Cancer in 2022. Surgery has long been recognized as a curative treatment for vulvar cancer, especially in the early stages. It offers the potential to remove the cancerous tissue entirely, providing a chance for a complete cure. The curative nature of surgery makes it a preferred choice for many patients and clinicians.

Vulvar cancer often presents as localized disease, primarily affecting the vulva and nearby lymph nodes. Surgery is highly effective at achieving localized disease control. Surgeons can precisely remove cancerous tissue while sparing healthy structures. This targeted approach minimizes the risk of cancer recurrence in the same area. Surgery plays a crucial role in the staging and accurate diagnosis of vulvar cancer. It allows for the assessment of the extent of the disease, including the size of the tumor and whether it has spread to nearby lymph nodes. This information is essential for determining the most appropriate treatment plan, even if surgery is not the primary treatment.

Surgery can be tailored to the individual patient's needs and the specific characteristics of their vulvar cancer. It may involve a wide local excision to remove the tumor while preserving as much healthy tissue as possible or more extensive procedures like radical vulvectomy or pelvic exenteration for advanced cases. This individualized approach ensures that patients receive the most suitable treatment. While surgery is often the primary treatment for vulvar cancer, it can be combined with other modalities like radiation therapy and chemotherapy when necessary. This multimodal approach allows for comprehensive cancer management, addressing both localized and systemic aspects of the disease.

### End-User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics house a multidisciplinary team of medical professionals with specialized expertise in vulvar cancer. This includes gynecologic oncologists, surgeons, radiation oncologists, medical oncologists, pathologists, and nurses with experience in cancer care. Their combined knowledge and skills ensure that patients receive tailored, evidence-based treatments.



The diagnostic capabilities of hospitals and clinics are crucial in vulvar cancer care. These facilities are equipped with advanced imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and positron emission tomography (PET) scans, which enable accurate staging and assessment of the disease's extent. Prompt and accurate diagnosis is essential for determining the most appropriate treatment plan.

Hospitals are the primary setting for surgical interventions in vulvar cancer cases. Surgical procedures, such as wide local excision, radical vulvectomy, lymph node dissection, and even pelvic exenteration for advanced cases, are often performed in hospital operating rooms. These procedures are critical for achieving local disease control and curative outcomes. Hospitals and clinics offer a wide range of treatment modalities for vulvar cancer patients, including radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Patients can receive these treatments in a controlled and monitored environment, ensuring both safety and efficacy. Supportive care is an integral part of vulvar cancer treatment. Hospitals and clinics provide comprehensive support services, including pain management, palliative care, psychological counseling, and rehabilitation. These services enhance patients' quality of life and alleviate treatment-related side effects. These factors collectively contribute to the growth of this segment.

## Regional Insights

North America emerged as the dominant player in the global Vulvar Cancer market in 2022, holding the largest market share in terms of value. North America boasts a robust healthcare infrastructure with state-of-the-art hospitals, clinics, and cancer centers. These facilities offer a wide range of diagnostic, treatment, and support services, making them central in the fight against vulvar cancer. The region is at the forefront of medical technology and innovation. Advanced diagnostic tools, surgical techniques, and treatment modalities are readily available, allowing for early detection and effective management of vulvar cancer. North American institutions actively engage in vulvar cancer research and clinical trials. This research contributes to the development of novel treatments, targeted therapies, and personalized medicine approaches for vulvar cancer patients. The region places significant emphasis on public health awareness campaigns. This has led to higher rates of early detection and patient engagement, resulting in better treatment outcomes. Although healthcare access remains a challenge in some areas, North America overall offers relatively good access to healthcare services. Patients can often seek timely medical attention, contributing to improved prognoses.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Vulvar Cancer players during the forecast period. Factors such as the APAC region is home to a large and aging population. As the population ages, the incidence of vulvar cancer is expected to rise, contributing to increased demand for healthcare services. Many APAC countries have been investing in their healthcare infrastructure. This includes the expansion of cancer treatment facilities, the adoption of advanced medical technologies, and the enhancement of healthcare delivery systems. Awareness about vulvar cancer and the importance of early detection is on the rise in the APAC region. Public health campaigns and educational initiatives are contributing to earlier diagnoses and improved outcomes. Efforts to improve healthcare access, particularly in rural and underserved areas, are underway. This ensures that a larger portion of the population has access to vulvar cancer diagnosis and treatment. The APAC region is increasingly participating in global research efforts and clinical trials. Collaboration with international institutions and pharmaceutical companies is facilitating the development and availability of advanced treatments. Many APAC governments are implementing cancer control programs, which include funding for cancer research, screening, and treatment. These initiatives are driving progress in vulvar cancer care.

### Key Market Players

Merck & Co. Inc.

Sanofi SA

Novartis AG

Astellas Pharma Inc.

Pfizer Inc.

Abbott Laboratories

Bristol-Myers Squibb Company

Takeda Pharmaceutical Company Limited

F. Hoffmann-La Roche Ltd

## Report Scope:

In this report, the Global Vulvar Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### Vulvar Cancer Market, By Cancer Type:

Vulvar Squamous Cell Carcinoma

Vulvar Melanoma

Adenocarcinoma

Basal Cell Carcinoma

### Vulvar Cancer Market, By Treatment Type:

Chemotherapy, Surgery

Laser Surgery

Excision

Skinning Vulvectomy

Radical Vulvectomy

Radiation Vulvectomy

Biologic Therapy

### Vulvar Cancer Market, By End-User:

Hospitals & Clinics

Research & Academic Institutes

Others

## Vulvar Cancer Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

## Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

## Available Customizations:

Global Vulvar Cancer market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary End-Users
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL VULVAR CANCER MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma)
  - 5.2.2. By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy)



- 5.2.3. By End-User (Hospitals & Clinics, Research & Academic Institutes, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2022)
- 5.3. Market Map

## **6. NORTH AMERICA VULVAR CANCER MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Cancer Type
  - 6.2.2. By Treatment Type
  - 6.2.3. By End-User
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Vulvar Cancer Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Cancer Type
      - 6.3.1.2.2. By Treatment Type
      - 6.3.1.2.3. By End-User
  - 6.3.2. Canada Vulvar Cancer Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Cancer Type
      - 6.3.2.2.2. By Treatment Type
      - 6.3.2.2.3. By End-User
  - 6.3.3. Mexico Vulvar Cancer Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Cancer Type
      - 6.3.3.2.2. By Treatment Type
      - 6.3.3.2.3. By End-User

## **7. EUROPE VULVAR CANCER MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Cancer Type
  - 7.2.2. By Treatment Type
  - 7.2.3. By End-User
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Vulvar Cancer Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Cancer Type
      - 7.3.1.2.2. By Treatment Type
      - 7.3.1.2.3. By End-User
  - 7.3.2. United Kingdom Vulvar Cancer Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Cancer Type
      - 7.3.2.2.2. By Treatment Type
      - 7.3.2.2.3. By End-User
  - 7.3.3. Italy Vulvar Cancer Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecasty
      - 7.3.3.2.1. By Cancer Type
      - 7.3.3.2.2. By Treatment Type
      - 7.3.3.2.3. By End-User
  - 7.3.4. France Vulvar Cancer Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Cancer Type
      - 7.3.4.2.2. By Treatment Type
      - 7.3.4.2.3. By End-User
  - 7.3.5. Spain Vulvar Cancer Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value
    - 7.3.5.2. Market Share & Forecast

- 7.3.5.2.1. By Cancer Type
- 7.3.5.2.2. By Treatment Type
- 7.3.5.2.3. By End-User

## **8. ASIA-PACIFIC VULVAR CANCER MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Cancer Type
  - 8.2.2. By Treatment Type
  - 8.2.3. By End-User
- 8.3. Asia-Pacific: Country Analysis
  - 8.3.1. China Vulvar Cancer Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Cancer Type
      - 8.3.1.2.2. By Treatment Type
      - 8.3.1.2.3. By End-User
  - 8.3.2. India Vulvar Cancer Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Cancer Type
      - 8.3.2.2.2. By Treatment Type
      - 8.3.2.2.3. By End-User
  - 8.3.3. Japan Vulvar Cancer Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Cancer Type
      - 8.3.3.2.2. By Treatment Type
      - 8.3.3.2.3. By End-User
  - 8.3.4. South Korea Vulvar Cancer Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value
    - 8.3.4.2. Market Share & Forecast
      - 8.3.4.2.1. By Cancer Type

- 8.3.4.2.2. By Treatment Type
- 8.3.4.2.3. By End-User
- 8.3.5. Australia Vulvar Cancer Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Cancer Type
    - 8.3.5.2.2. By Treatment Type
    - 8.3.5.2.3. By End-User

## **9. SOUTH AMERICA VULVAR CANCER MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Cancer Type
  - 9.2.2. By Treatment Type
  - 9.2.3. By End-User
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Vulvar Cancer Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Cancer Type
      - 9.3.1.2.2. By Treatment Type
      - 9.3.1.2.3. By End-User
  - 9.3.2. Argentina Vulvar Cancer Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Cancer Type
      - 9.3.2.2.2. By Treatment Type
      - 9.3.2.2.3. By End-User
  - 9.3.3. Colombia Vulvar Cancer Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast
      - 9.3.3.2.1. By Cancer Type
      - 9.3.3.2.2. By Treatment Type

#### 9.3.3.2.3. By End-User

## **10. MIDDLE EAST AND AFRICA VULVAR CANCER MARKET OUTLOOK**

### 10.1. Market Size & Forecast

#### 10.1.1. By Value

### 10.2. Market Share & Forecast

#### 10.2.1. By Cancer Type

#### 10.2.2. By Treatment Type

#### 10.2.3. By End-User

### 10.3. MEA: Country Analysis

#### 10.3.1. South Africa Vulvar Cancer Market Outlook

##### 10.3.1.1. Market Size & Forecast

###### 10.3.1.1.1. By Value

##### 10.3.1.2. Market Share & Forecast

###### 10.3.1.2.1. By Cancer Type

###### 10.3.1.2.2. By Treatment Type

###### 10.3.1.2.3. By End-User

#### 10.3.2. Saudi Arabia Vulvar Cancer Market Outlook

##### 10.3.2.1. Market Size & Forecast

###### 10.3.2.1.1. By Value

##### 10.3.2.2. Market Share & Forecast

###### 10.3.2.2.1. By Cancer Type

###### 10.3.2.2.2. By Treatment Type

###### 10.3.2.2.3. By End-User

#### 10.3.3. UAE Vulvar Cancer Market Outlook

##### 10.3.3.1. Market Size & Forecast

###### 10.3.3.1.1. By Value

##### 10.3.3.2. Market Share & Forecast

###### 10.3.3.2.1. By Cancer Type

###### 10.3.3.2.2. By Treatment Type

###### 10.3.3.2.3. By End-User

## **11. MARKET DYNAMICS**

### 11.1. Drivers & Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

## **13. GLOBAL VULVAR CANCER MARKET: SWOT ANALYSIS**

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Merck & Co. Inc.
- 14.2. Sanofi SA
- 14.3. Novartis AG
- 14.4. Astellas Pharma Inc.
- 14.5. Pfizer Inc.
- 14.6. Abbott Laboratories
- 14.7. Bristol-Myers Squibb Company
- 14.8. Takeda Pharmaceutical Company Limited
- 14.9. F. Hoffmann-La Roche Ltd

## **15. STRATEGIC RECOMMENDATIONS**

## **16. ABOUT US & DISCLAIMER**



## I would like to order

Product name: Vulvar Cancer Market – Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy), By End-User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region, Competition

Product link: <https://marketpublishers.com/r/VE35DA8A7548EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VE35DA8A7548EN.html>